Dr. Ashworth Brings Decades of Scientific and Clinical Experience Translating Synthetic Lethality Discoveries into Precision Cancer Therapies ...

Using the concept of synthetic lethality to treat cancer how now been tried and tested with PARP inhibitors, and it has the potential to be widely applicable across many cancer types. “Last year, I ...

Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine.

Poly adenosine diphosphate-ribose polymerase inhibitors, an important class of anticancer drugs, employ synthetic lethality strategy and are particularly effective against cancers with genetic ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...